H.C. Wainwright analyst Matthew Keller raised the firm’s price target on InflaRx (IFRX) to $8 from $6 and keeps a Buy rating on the shares based on the company’s adjusted clinical focus on ANCA-associated vasculitis, inflammatory renal diseases, and the potential partnering of the hidradenitis suppurativa program following last week’s corporate update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
- InflaRx to develop izicopan in AAV
- InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
- InflaRx Files Q1 2026 Financials with SEC via Form 6-K
- InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study